Kathy Giusti

Last updated
Kathy Giusti
GiustiKG (cropped).jpg
Kathy Giusti in 2021
Born1958
Education Bachelor of Science in Nursing
Alma mater
Occupations
  • Co-founder, Multiple Myeloma Research Foundation (MMRF)
  • Co-chair, Harvard Business School (HBS) Kraft Precision Medicine Accelerator
SpousePaul Giusti
Children2

Kathy Giusti is a business leader, healthcare professional, and author. [1] [2] She is a two-time cancer survivor having been diagnosed with multiple myeloma and breast cancer. Kathy Co-Founded the Multiple Myeloma Research Foundation (the MMRF) [3] where she was CEO and president for nearly two decades. She also co-chaired the Harvard Business School (HBS) Kraft Precision Medicine Accelerator, [4] which she helped found, and was a Senior Fellow at Harvard Business School. [5]

Contents

Giusti has been named one of Time magazine's 100 Most Influential People in the world. [6] and named one of Fortune's list of Worlds' 50 Greatest Leaders. [7]

Career

Early career

Giusti held executive positions in consumer marketing with Gillette/Procter & Gamble[ citation needed ] and in the pharmaceutical sector with Merck & Co. and G.D. Searle & Company (now Pfizer). [5]

The Multiple Myeloma Research Foundation

In 1998, with her identical twin sister Karen Andrews, Giusti founded the Multiple Myeloma Research Foundation (the MMRF). The MMRF’s mission is to accelerate a cure for multiple myeloma patients. [3]

As founder and CEO, Giusti has led the MMRF in establishing the Multiple Myeloma Research Consortium (MMRC), the MMRF CoMMpass™ study, [8] CureCloud, [9] the Right Track, [10] and the Myeloma Investment Fund. [11]

Under Giusti the MMRF has raised more than $500 million to fund research, 15 drugs have been approved to treat multiple myeloma, and many clinical trials are underway. [12] These efforts have accelerated the pace at which treatments are brought to patients and more than tripled patients' survival. [1]

Harvard Business School (HBS)

Giusti joined the Harvard Business School faculty as Senior Fellow, Co-Chairing the HBS Kraft Precision Medicine Accelerator, a $20 million endowed program provided by Robert Kraft and the Kraft Family Foundation. [4] The Kraft Accelerator created The Kraft Precision Medicine Accelerator Playbook for Cures. [13]

Diagnosis

In 1996, Kathy Giusti was diagnosed with multiple myeloma, an incurable blood cancer. When diagnosed, Giusti was 37 years old and was given three years to live. [14] In 2022, Giusti was diagnosed with early-stage breast cancer as well. [15]

Appointments

Giusti has been appointed to multiple positions and advisory boards, all with a focus on developing cures for cancer. These include:

Recognition

Giusti has received numerous awards for her leadership:  

Publications

Kathy has authored or co-authored multiple articles in business, consumer, and scientific publications:

References

  1. 1 2 Mukherjee, Sy (2016-05-22). "These 3 Former Business Leaders Are Disrupting Medicine". Fortune . Retrieved 2021-02-19.
  2. ↑ Kerr, Nancy (20 February 2024). "'Fatal to Fearless': Facing a Deadly Cancer Diagnosis and Fighting Back". AARP. Retrieved 28 October 2024.
  3. 1 2 "About the Multiple Myeloma Research Foundation | The MMRF". themmrf.org. Retrieved 2021-02-19.[ non-primary source needed ]
  4. 1 2 "Kraft Accelerator - Harvard Business School". www.hbs.edu. Retrieved 2021-02-19.[ non-primary source needed ]
  5. 1 2 Young, Susan (24 October 2016). "Health Care Pioneer Giusti Named McCance Senior Fellow at HBS". www.alumni.hbs.edu. Retrieved 2021-02-19.
  6. ↑ Couric, Katie (2011-04-21). "The 2011 TIME 100 - TIME". Time. ISSN   0040-781X . Retrieved 2021-02-19.
  7. ↑ Goyette, Jay (2014-03-24). "UVM Alumna Kathy Giusti Named One of Fortune Magazine's 'World's 50 Greatest Leaders'". www.uvm.edu. Retrieved 2021-02-19.
  8. 1 2 "Giving hope and inspiration to cancer patients around the globe". www.alumni.hbs.edu. 24 April 2014. Retrieved 2021-02-19.
  9. ↑ MMRF (2020-07-14). "MMRF Launches CureCloud to Democratize Healthcare for Cancer Patients". themmrf.org. Archived from the original on August 6, 2020. Retrieved 2021-02-19.
  10. ↑ Giusti, Kathy; Marcus, Lori Tauber (12 February 2019). "4 Important Steps to Take After a Cancer Diagnosis". Time. Retrieved 2021-02-19.[ non-primary source needed ]
  11. ↑ MMRF (2019-04-23). "Multiple Myeloma Research Foundation (MMRF) Launches Innovative Fund to Accelerate New Myeloma Treatments". themmrf.org. Archived from the original on October 24, 2020. Retrieved 2021-02-19.
  12. ↑ MMRF (2020-12-04). "The MMRF Drives Unparalleled Advances for Multiple Myeloma Patients". themmrf.org. Archived from the original on January 26, 2021. Retrieved 2021-02-19.
  13. ↑ "Use the Tools". www.hbs.edu. Retrieved 2021-02-19.[ non-primary source needed ]
  14. ↑ Kincaid, Ellie (2018-03-26). "She Was Given Three Years To Live. So She Transformed Cancer Research". Forbes . Retrieved 2021-02-19.
  15. ↑ Giusti, Kathy (17 June 2022). "I've Been Diagnosed With Two Different Cancers—This Is What I've Learned". Prevention. Retrieved 2022-06-17.Giusti
  16. ↑ "Kathy Giusti, M.B.A." National Institutes of Health (NIH). 2020-08-27. Archived from the original on April 23, 2018. Retrieved 2021-02-19.[ non-primary source needed ]
  17. ↑ "FasterCures Changemakers: Disruptive Philanthropy for Patients". milkeninstitute.org. Archived from the original on August 14, 2020. Retrieved 2021-02-19.
  18. ↑ "Multiple Myeloma Research Foundation (MMRF) Founder, CEO Receives American Society of Clinical Oncology's Partners In Progress Award". BioSpace. Retrieved 2021-02-19.[ dead link ]
  19. ↑ "EQRx Appoints Kathy Giusti to Board of Directors". EQRx. 2021-09-27. Archived from the original on September 27, 2021. Retrieved 2021-09-27.
  20. ↑ "34 Leaders Who Are Changing Health Care". Fortune . Retrieved 2021-02-19.
  21. ↑ Giusti, Kathy (2013-06-20). "Democratizing the Science, Accelerating the Cure". whitehouse.gov. Retrieved 2021-02-19.
  22. ↑ "Kathryn E. Giusti, MBA 1985". www.alumni.hbs.edu. January 2009. Retrieved 2021-02-19.
  23. ↑ "Personalized Medicine Coalition - Advocates for precision medicine : PMC Press Releases : Press Releases : Personalized Medicine Coalition Recognizes Kathy Giusti with Award for Leadership". www.personalizedmedicinecoalition.org. Archived from the original on March 18, 2015. Retrieved 2021-02-19.
  24. ↑ "Giusti, Pelosi, and Sawyers to Receive American Association for Cancer Research Distinguished Public Service Awards | News Releases". American Association for Cancer Research (AACR). 2021-04-05. Retrieved 2021-04-21.[ non-primary source needed ]
  25. ↑ "Woman of the Year Past Recipients | HBA". www.hbanet.org. Archived from the original on May 22, 2015. Retrieved 2021-02-19.
  26. ↑ "Reducing Racial Disparities in Cancer Treatment Demands Collective Action". Harvard Business Review . 2022-06-13. Retrieved 2022-06-13.
  27. ↑ "Reducing Racial Disparities in Cancer Outcomes". Harvard Business Review . 2022-01-17. Retrieved 2022-01-17.
  28. ↑ "Addressing Demographic Disparities in Clinical Trials". Harvard Business Review . 2021-06-11. ISSN   0017-8012 . Retrieved 2021-06-21.
  29. ↑ "A New Playbook for Cure-Seeking Nonprofits". The Journal of Precision Medicine. Retrieved 2021-02-19.
  30. ↑ "How Nonprofit Foundations Can Sustainably Fund Disease Research". Harvard Business Review . 2020-09-30. ISSN   0017-8012 . Retrieved 2021-02-19.
  31. ↑ "What It Takes to Lead a Disease Research Foundation". Harvard Business Review . 2020-08-18. ISSN   0017-8012 . Retrieved 2021-02-19.
  32. ↑ "How Medical Nonprofits Set Winning Strategy". Harvard Business Review . 2020-03-06. ISSN   0017-8012 . Retrieved 2021-02-19.
  33. ↑ "One Obstacle to Curing Cancer: Patient Data Isn't Shared". Harvard Business Review . 2016-11-28. ISSN   0017-8012 . Retrieved 2021-02-19.
  34. ↑ "What Cancer Researchers Can Learn from Direct-to-Consumer Companies". Harvard Business Review . 2017-01-12. ISSN   0017-8012 . Retrieved 2021-02-19.
  35. ↑ Giusti, Kathy; Young, Anne Quinn; Lehrhaupt, Kerri (May–June 2018). "Closing Knowledge Gaps to Optimize Patient Outcomes and Advance Precision Medicine". Cancer Journal (Sudbury, Mass.). 24 (3): 144–151. doi:10.1097/PPO.0000000000000319. ISSN   1540-336X. PMID   29794540. S2CID   44094784.
  36. ↑ Giusti, Kathy; Young, Anne Quinn; Winget, Melissa; Lehrhaupt, and Kerri (2017-04-11). "Understanding Differences in Critical Decisions in the Multiple Myeloma Patient Journey in the Era of Precision Medicine". American Journal of Hematology/Oncology. 13 (3).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.